Scienture (SCNX) 10-Q 26 Jul 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Jul. 22, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-39199
Entity Registrant Name	TRxADE HEALTH, INC.
Entity Central Index Key	0001382574
Entity Tax Identification Number	46-3673928
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3840 Land O’ Lakes Blvd.
Entity Address, City or Town	Land O’ Lakes
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34639
City Area Code	(800)
Local Phone Number	261-0281
Title of 12(b) Security	Common Stock, $0.00001 Par Value Per Share
Trading Symbol	MEDS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,161,457

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets
Cash	$ 4,519,983	$ 5,919,578
Accounts Receivable, net	1,504,037	805,043
Inventory	139,117	1,257,754
Prepaid Assets	373,030	151,248
Other Receivables		1,087,675
Total Current Assets	6,536,167	9,221,298
Property Plant and Equipment, Net	15,006	162,397
Other Assets
Deposits	21,636	21,636
Right of use leased assets	323,221	387,371
Total Assets	6,896,030	9,792,702
Current Liabilities
Accounts Payable	168,374	256,829
Accrued Liabilities	377,049	219,256
Current Portion Lease Liabilities	90,628	131,153
Customer Deposits		10,000
Notes Payables– Related Party	225,000	225,000
Total Current Liabilities	861,051	842,238
Long Term Liabilities
Other Long-Term Liabilities — Leases	248,002	271,306
Total Liabilities	1,109,053	1,113,544
Stockholders’ Equity
Series A Preferred Stock, $0.00001 par value shares authorized; none issued and outstanding as of June 30, 2021, and December 31, 2020
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 8,161,457 and 8,093,199 shares issued and outstanding as of June 30, 2021, and December 31, 2020, respectively	81	81
Additional Paid-in Capital	19,948,245	19,610,631
Accumulated Deficit	(14,161,349)	(10,931,554)
Total Stockholders’ Equity	5,786,977	8,679,158
Total Liabilities and Stockholders’ Equity	$ 6,896,030	$ 9,792,702

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share		$ 0.00001
Preferred Stock, Shares Outstanding		0
Common Stock, Par or Stated Value Per Share		$ 0.00001
Common Stock, Shares Authorized		100,000,000
Common Stock, Shares, Outstanding	8,161,457	8,093,199

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 1,898,254	$ 6,592,637	$ 4,951,489	$ 8,795,957
Cost of Sales	1,056,863	4,587,865	2,726,787	5,151,049
Gross Profit	841,391	2,004,772	2,224,702	3,644,908
Operating Expenses
Loss on Inventory Investment	1,225,141		1,225,141
General and Administrative	2,185,838	2,540,049	4,213,404	3,991,958
Operating (Loss) Income	(2,569,588)	(535,277)	(3,213,843)	(347,050)
Interest Expense	(8,688)	(7,310)	(15,952)	(15,234)
Net (Loss) Income	$ (2,578,276)	$ (542,587)	$ (3,229,795)	$ (362,284)
Net (Loss) Income per Common Share – Basic and Diluted:	$ (0.32)	$ (0.07)	$ (0.40)	$ (0.05)
Weighted average Common Shares Outstanding – Basic and Diluted	8,122,206	7,580,977	8,107,864	7,324,512

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019		$ 65	$ 12,535,655	$ (8,395,503)	$ 4,140,217
Beginning balance, shares at Dec. 31, 2019		6,539,415
Common Stock issued from offering		$ 10	5,994,414		5,994,424
Common Stock issued from offering, shares		922,219
Fractional shares issued due to reverse split
Fractional shares issued due to reverse split, shares		40
Stock Issuance Costs			(820,586)		(820,586)
Warrants Exercised for Cash			1,352		1,352
Warrants Exercised for Cash, shares		22,529
Warrants Expense			79,089		79,089
Options Expense			61,997		61,997
Net Loss				180,303	180,303
Options Expense			501		501
Options Exercised for Cash, shares		167
Ending balance, value at Mar. 31, 2020		$ 75	17,852,422	(8,215,200)	9,637,297
Ending balance, shares at Mar. 31, 2020		7,484,370
Beginning balance, value at Dec. 31, 2019		$ 65	12,535,655	(8,395,503)	4,140,217
Beginning balance, shares at Dec. 31, 2019		6,539,415
Net Loss					(362,284)
Ending balance, value at Jun. 30, 2020		$ 81	18,909,083	(8,757,787)	10,151,377
Ending balance, shares at Jun. 30, 2020		8,062,337
Beginning balance, value at Mar. 31, 2020		$ 75	17,852,422	(8,215,200)	9,637,297
Beginning balance, shares at Mar. 31, 2020		7,484,370
Warrants Exercised for Cash		$ 4	21,596		21,600
Warrants Exercised for Cash, shares		360,002
Warrants Expense			21,294		21,294
Common Stock Issued for Services		2	829,865		829,867
Net Loss				(542,587)	(542,587)
Common Stock issued for Services, shares		217,965
Options Expense			183,906		183,906
Ending balance, value at Jun. 30, 2020		$ 81	18,909,083	(8,757,787)	10,151,377
Ending balance, shares at Jun. 30, 2020		8,062,337
Beginning balance, value at Dec. 31, 2020		$ 81	19,610,631	(10,931,554)	8,679,158
Beginning balance, shares at Dec. 31, 2020		8,093,199
Common Stock Issued for Services			98,247		98,247
Options Expense			75,738		75,738
Net Loss				(651,519)	(651,519)
Ending balance, value at Mar. 31, 2021		$ 81	19,784,616	(11,583,073)	8,201,624
Ending balance, shares at Mar. 31, 2021		8,093,199
Beginning balance, value at Dec. 31, 2020		$ 81	19,610,631	(10,931,554)	8,679,158
Beginning balance, shares at Dec. 31, 2020		8,093,199
Net Loss					(3,229,795)
Ending balance, value at Jun. 30, 2021		$ 81	19,948,245	(14,161,349)	5,786,977
Ending balance, shares at Jun. 30, 2021		8,161,457
Beginning balance, value at Mar. 31, 2021		$ 81	19,784,616	(11,583,073)	8,201,624
Beginning balance, shares at Mar. 31, 2021		8,093,199
Common Stock Issued for Services			100,416		100,416
Options Expense			61,392		61,392
Net Loss				(2,578,276)	(2,578,276)
Common Stock issued for Services, shares		37,905
Options Expense			1,821		1,821
Options Exercised for Cash, shares		30,353
Ending balance, value at Jun. 30, 2021		$ 81	$ 19,948,245	$ (14,161,349)	$ 5,786,977
Ending balance, shares at Jun. 30, 2021		8,161,457

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating Activities:
Net Income (Loss)	$ (3,229,795)	$ (362,284)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation Expense	3,500	2,500
Options expense	137,130	245,903
Warrant Expense		100,383
Common Stock Issued for Services	198,663	829,867
Bad Debt Expense	(10,000)	9,000
Loss on Inventory Investments	1,225,141
Amortization of right of use asset	64,150	47,799
Changes in operating assets and liabilities:
Accounts Receivable	(688,994)	(2,761,331)
Prepaid Assets and other Current Assets	(221,782)	(217,615)
Inventory	1,118,637	(1,762,113)
Deposits for Inventory Purchases		(309,000)
Other Receivables	6,425
Lease Liability	(63,829)	(42,477)
Accounts Payable	(88,455)	(17,871)
Customer Deposits	(10,000)	3,574
Accrued Liabilities and Other Liabilities	157,793	250,998
Net Cash used in operating activities	(1,401,416)	(3,982,667)
Investing Activities:
Purchase of Fixed Assets		(23,505)
Net Cash used in Investing activities		(23,505)
Financing Activities:
Stock Issuance Costs		(732,355)
Proceeds from exercise of Warrants		22,952
Proceeds from exercise of Stock Options	1,821	501
Proceeds from Issuance of Common Stock		5,994,424
Net Cash provided by financing activities	1,821	5,285,522
Net increase (decrease) in Cash	(1,399,595)	1,279,350
Cash at Beginning of the Period	5,919,578	2,871,694
Cash at End of the Period	4,519,983	4,151,044
Supplemental Cash Flow Information
Cash Paid for Interest	4,702	3,984
Cash Paid for Income Taxes

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION TRxADE HEALTH, INC. (“ we our Trxade Company 100 Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications and a community-based model offering home delivery services to patients. Alliance Pharma Solutions, LLC, has developed a same-day pharmaceutical delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019, which investment was divested in February 2020. Bonum Health, LLC, was formed to hold certain telehealth assets acquired in October 2019. The “ Bonum Health Hub 143,891 . The Bonum Health mobile application is available on a subscription basis, primarily as a stand-alone telehealth software application that can be licensed on a business-to-business (B2B) model to clients as an employment health benefit for the clients’ employees. MedCheks, LLC, was formed in January 2021 and is a patient-centered, digital, precision healthcare platform that lets patients consolidate and control their health data via a digital Health Passport. The digital Health Passport allows users to share their health profile, tests and vaccinations simply and safely. Secured in a blockchain, the Health Passport includes health and vaccination status verification via a QR code (a two-dimensional machine-readable optical label), which is available for travel, entry into stadiums, concert venues, events, offices, industrial plants, warehouses, and other physical access points. MedCheks Health Passport stores all of a user’s health records securely in one place. Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2020, as reported in the Company’s Annual Report on Form 10-K have been omitted. Accounts Receivable – 0 9,000 10,000 0 The Company has a concentration in Account Receivable with a single customer for the amount of $ 630,000 Income (loss) Per Common Share 75,875 432,164 The following table sets forth the computation of basic and diluted Income (Loss) per Share: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE 2021 2020 2021 2020 For three months ended June 30, For six months ended June 30, 2021 2020 2021 2020 Numerator: Net (Loss) Income $ (2,578,276 ) $ (542,587 ) $ (3,229,795 ) $ (362,284 ) Numerator for basic and diluted EPS - income available to common Shareholders (2,578,276 ) $ (542,587 ) (3,229,795 ) $ (362,284 ) Denominator: Denominator for basic and diluted EPS – Weighted average shares 8,122,206 7,580,977 8,107,864 7,324,512 Basic and Diluted (Loss) Income per common share $ (0.32 ) $ (0.07 ) $ (0.40 ) $ (0.05 )

SHORT TERM DEBT _ RELATED PARTI

SHORT TERM DEBT – RELATED PARTIES	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
SHORT TERM DEBT – RELATED PARTIES	NOTE 2– SHORT TERM DEBT – RELATED PARTIES In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $ 300,000 promissory note was issued to Nikul Panchal, a non-executive officer of the Company, accruing simple interest at the rate of 10 % per annum, payable annually, and having a maturity date on October 15, 2021 . In October 2019, $ 75,000 of the note was converted into 25,000 common shares at $ 3.00 per share, leaving $ 225,000 of principal owed under the promissory note. There was a loss recognized on this conversion of $ 76,500 . At June 30, 2021, and December 31, 2020, total related party debt was $ 225,000 .

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	STOCKHOLDERS’ EQUITY 2020 Equity Compensation Awards On April 14, 2020, the Compensation Committee approved the grant of (a) 5,000 shares of restricted common stock to the Company’s legal counsel; and (b) 12,500 shares of restricted common stock to Howard A. Doss, the Company’s Chief Financial Officer, which shares vest at the rate of ¼ th 107,100 and the Company recognized stock-based compensation expense of $ 26,775 for the six months ended June 30, 2021. On April 14, 2020, the three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 8,987 shares of restricted stock, which vest at the rate of ¼ th 165,000 and the Company recognized stock-based compensation expense of $ 41,250 for the six months ended June 30, 2021. 2021 Equity Compensation Awards On April 15, 2021, the Board of Directors, with the recommendation of the Compensation Committee, approved the grant of options to purchase an aggregate of 17,500 shares of our common stock to certain employees of the Company, in consideration for services to be rendered by such individuals through 2025. The options vest at the rate of ¼ th five years 4.76 per share, the closing price of the Company’s common stock on the date of the grant of such options. In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on April 15, 2021, the then three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 10,721 shares of restricted stock, valued at $ 55,000 ($ 5.13 per share) based on the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the effective date of the grant, April 1, 2021, which vest at the rate of ¼ th 165,000 and the Company recognized stock-based compensation expense of $ 41,250 for the six months ended June 30, 2021. Common Shares totaling 16,082 were cancelled on May 27, 2021, when the director services of Mr. Peterson and Ms. Tenaerts were terminated. The Board of Directors of the Company, on May 27, 2021, confirmed the vesting of 2,680 In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on May 27, 2021, the Board of Directors awarded Charles L. Pope, and Christine L. Jennings, each independent members of the Board of Directors appointed to the Board of Directors on May 27, 2021, 10,912 41,250 3.78 Employment Agreement with Suren Ajjarapu, Chief Executive Officer In connection with our employment agreement with Mr. Suren Ajjarapu, our Chief Executive Officer, which was effective on April 14, 2020, we granted 49,020 300,000 72,062 49,020 391,841 Stock Repurchase Program On May 27, 2021, the Board of Directors of the Company authorized and approved a share repurchase program for up to $ 1 There is no time frame for the repurchase program, and such program will remain in place until a maximum of $1.0 million of the Company’s common stock has been repurchased or until such program is suspended or discontinued by the Board of Directors. no

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2021
Warrants
WARRANTS	NOTE 4 – WARRANTS For the six-month period ended June 30, 2021, no 6,876 The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. The compensation cost related to the warrants granted was $ 0 and $ 100,383 for the six months ended June 30, 2021, and 2020, respectively. The Company’s outstanding and exercisable warrants as of June 30, 2021, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2020 82,751 $ 1.33 2.73 $ 352,951 Warrants granted - $ - - - Warrants expired or forfeited (6,876 ) $ 9.00 - - Warrants exercised - $ - - - Warrants Outstanding as of June 30, 2021 75,875 $ 0.64 2.45 $ 286,939 Warrants Exercisable as of June 30, 2021 53,347 $ 0.88 1.25 $ 188,717

OPTIONS

OPTIONS	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
OPTIONS	NOTE 5 – OPTIONS The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 2,333,333 2,000,000 st beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. For the six-month period ended June 30, 2021, options to purchase 36,700 shares were granted, none were forfeited, and none expired. The options granted during the period vest over a four-year period, the weighted average exercise price was $ 5.74 per share and the options have a term of 5 years. For the six-month period ended June 30, 2021, options to purchase 30,353 shares of common stock were exercised, for 30,353 shares of common stocks resulting in proceeds of $ 1,821 . The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended June 30, 2021: SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS Expected dividend yield 0 % Weighted-average expected volatility 102 - 207 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5 Total compensation cost related to stock options granted was $ 137,130 and $ 245,903 for the six-months ended June 30, 2021, and 2020, respectively. The following table represents stock option activity for the six-month period ended June 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2020 425,817 $ 4.44 5.33 $ 597,322 Options Exercisable as of December 31, 2020 282,167 $ 4.52 4.56 $ 384,226 Options granted 36,700 $ 5.74 4.69 - Options forfeited - $ - - - Options expired - $ - - - Options exercised (30,353 ) $ 0.06 - - Options Outstanding as of June 30, 2021 432,164 $ 4.86 5.15 $ 267,985 Options Exercisable as of June 30, 2021 287,840 $ 4.93 4.77 $ 166,419

OTHER RECEIVABLES

OTHER RECEIVABLES	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
OTHER RECEIVABLES	OTHER RECEIVABLES In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, LLC (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $ 500,000 and Studebaker would deliver 180,000 boxes of nitrile gloves by August 14, 2020. Integra wired the $ 500,000 to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021 the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgement but denied the motion to dismiss. Studebaker then filed an answer and affirmative defenses, and we filed a motion to strike their affirmative defenses. The court has not yet ruled, but the discovery phase of the litigation has commenced. The Company believes it will prevail on the merits but cannot determine the timing of the judgment or the amount ultimately collected. At June 30, 2021, the $ 500,000 was recorded as Loss on Inventory Investment. In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $ 581,250 and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver 150,000 boxes of nitrile gloves within 45 days. Integra wired the $ 581,250 to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $ 581,250 and Crecom has acknowledged that Integra is entitled to a refund, but to date Crecom has failed to return Integra’s money. In February 2021, Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. Crecom filed an appearance on March 1, 2021. In April 2021, an Application for Summary Judgement was filed with the court, and on May 25, 2021, the Court extracted the sealed application, and a copy thereof was served on Crecom’s attorneys and Crecom, 14 days later, filed an Affidavit in Reply with the court alleging that there are issues to be tried and that this case must go to a full trial. On June 28, 2021, the court directed both parties to file their written submissions/arguments in relation to the application for summary judgment on or before July 12, 2021, and scheduled a hearing thereon for August 26, 2021. If a judgment is entered against Crecom, the process of executing the judgment, and ultimately attempting to collect on the judgment, can take three to six months. The Company believes that it will prevail in the lawsuit filed; but the steps to enforce a judgement in Malaysia, if any, may be cumbersome, time consuming or costly. The Company cannot determine the timing of the judgement, nor the amount ultimately collected. At June 30, 2021, the $ 581,250 was recorded as Loss on Inventory Investment. Bonum Health, LLC, was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” was launched in November 2019 and was expected to be operational in April 2020; however, due to the COVID-19 pandemic the Company does not anticipate installations moving forward and has taken a write off of the hubs purchased on June 30, 2021, in Loss on Inventory Investments of $ 143,891 .

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The complaint sought $ 425,000 1,275,000 However, in September 2020, the plaintiffs filed a similar complaint (alleging substantially similar facts) in the United States District Court for the Middle District of Florida, Tampa Division (Case 8:20-cv-02263), against the same defendants but adding Westminster Pharmaceuticals, LLC, our former wholly-owned subsidiary (“Westminster”), and raising claims for alleged fraud under Section 10(b) and Rule 10b-5 of the Exchange Act; joint and several liability under 15 U.S.C. Code 78t (against Trxade, Inc.); fraudulent transactions of securities under the Florida Securities Act (against all of the defendants except Trxade); and sale of unregistered securities under the Florida Securities Act (against all of the defendants except Trxade). The total amount of damages sought is unclear but is thought to be in excess of $ 425,000 . To the Company’s and Mr. Ajjarapu’s knowledge, the complaint has no merit whatsoever and each of the Company and Mr. Ajjarapu intend to defend themselves and oppose the relief sought in the complaint. The Company is not currently accused of any direct misconduct; instead, the Company is alleged to be liable for the acts of certain or all of the other defendants. The Company would likely only incur liability if some or all of the other defendants were found liable to plaintiffs and the Company is found to be jointly and severally liable for the actions of such other defendant or defendants. The lawsuit claims approximately $ 450,000 in damages; however, based on facts currently known, the Company assesses the likelihood of any material loss as remote.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases
LEASES	NOTE 8 – LEASES The Company elected the practical expedient under Accounting Standards Update (ASU) 2018-11 “Leases: Targeted Improvements” which allows the Company to apply the transition provision for Topic 842 at the Company’s adoption date instead of at the earliest comparative period presented in the financial statements. Therefore, the Company recognized and measured leases existing at January 1, 2019, but without retrospective application. In addition, the Company elected the optional practical expedient permitted under the transition guidance which allows the Company to carry forward the historical accounting treatment for existing leases upon adoption. No impact was recorded to the beginning retained earnings for Topic 842. The Company has two operating leases for corporate offices. The following table outlines the details: SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of right-of-use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The Company decided not to renew the corporate office lease (Lease 1) in January 2021; however, the parties subsequently negotiated a one-year lease at the same location. The Company determined that the decision to not renew Lease 1 changed the corresponding lease term which required remeasurement of the lease liability resulting in the reduction of the right-of-use asset and the associated lease liability by $ 384,110 . The reassessment of the lease term did not change the existing classification and the lease is still classified as an operating lease. The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of June 30, 2021. SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES 2021 Amounts due within twelve months of June 30 2021 $ 117,109 2022 49,824 2023 51,327 2024 52,866 2025 54,452 Thereafter 133,300 Total minimum lease payments 458,878 Less: effect of discounting (120,248 ) Present value of future minimum lease payments 338,631 Less: current obligations under leases 90,628 Long-term lease obligations $ 248,003 For the six months ended June 30, 2021, and 2020, amortization of Right of Use Assets was $ 64,150 and $ 47,799 , respectively. For the six months ended June 30, 2021, and 2020, amortization of Lease Liability was $ 63,829 and $ 42,477 , respectively.

SEGMENT REPORTING

SEGMENT REPORTING	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 9 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Six Months Ended June 30, 2021 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,387,360 $ 832,243 $ 1,715,466 $ 16,420 $ 4,951,489 Gross Profit $ 2,387,048 $ 94,033 $ (272,461 ) $ 16,082 $ 2,224,702 Segment Assets $ 1,587,888 $ (417,731 ) $ 1,301,196 $ 4,424,677 $ 6,896,030 Segment Profit (Loss) $ 980,562 $ (47,901 ) $ (1,656,786 ) $ (2,505,670 ) $ (3,229,795 ) Six Months Ended June 30, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,914,537 $ 870,637 $ 5,003,523 $ 7,260 $ 8,795,957 Gross Profit $ 2,914,537 $ 74,835 $ 648,276 $ 7,260 $ 3,644,908 Segment Assets $ 1,793,747 $ 243,603 $ 5,041,989 $ 4,652,944 $ 11,732,283 Segment Profit (Loss) $ 1,872,862 $ (72,955 ) $ 369,370 $ (2,531,561 ) $ (362,284 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – On July 18, 2021 the Board of Directors approved an “at-the-market” offering for the sale of up to $ 9 million in shares of the common stock under which the Distribution Agent may sell the Offering shares in public market transactions reported on the consolidated tape or privately negotiated transactions which may include block trades pursuant to and in connection with the Company’s previously filed Form S-3 Shelf Registration Statement filed with the Securities and Exchange Commission on August 28, 2020 and declared effective by the Commission on September 3, 2020 (File Number: 333-248473) and the Prospectus Supplement has not been filed with the Commission under Rule 424(b)(5) as of the date of this filing. On July 18, 2021, our Board of Directors paused the Stock Repurchase Program until the “at-the-market” offering is complete.

ORGANIZATION AND BASIS OF PRE_2

ORGANIZATION AND BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE	The following table sets forth the computation of basic and diluted Income (Loss) per Share: SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE 2021 2020 2021 2020 For three months ended June 30, For six months ended June 30, 2021 2020 2021 2020 Numerator: Net (Loss) Income $ (2,578,276 ) $ (542,587 ) $ (3,229,795 ) $ (362,284 ) Numerator for basic and diluted EPS - income available to common Shareholders (2,578,276 ) $ (542,587 ) (3,229,795 ) $ (362,284 ) Denominator: Denominator for basic and diluted EPS – Weighted average shares 8,122,206 7,580,977 8,107,864 7,324,512 Basic and Diluted (Loss) Income per common share $ (0.32 ) $ (0.07 ) $ (0.40 ) $ (0.05 )

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2021
Warrants
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS	The Company’s outstanding and exercisable warrants as of June 30, 2021, are presented below: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2020 82,751 $ 1.33 2.73 $ 352,951 Warrants granted - $ - - - Warrants expired or forfeited (6,876 ) $ 9.00 - - Warrants exercised - $ - - - Warrants Outstanding as of June 30, 2021 75,875 $ 0.64 2.45 $ 286,939 Warrants Exercisable as of June 30, 2021 53,347 $ 0.88 1.25 $ 188,717

OPTIONS (Tables)

OPTIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended June 30, 2021: SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS Expected dividend yield 0 % Weighted-average expected volatility 102 - 207 % Weighted-average risk-free interest rate 0.25 % Expected life of options 5
SCHEDULE OF STOCK OPTION ACTIVITY	The following table represents stock option activity for the six-month period ended June 30, 2021: SCHEDULE OF STOCK OPTION ACTIVITY Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2020 425,817 $ 4.44 5.33 $ 597,322 Options Exercisable as of December 31, 2020 282,167 $ 4.52 4.56 $ 384,226 Options granted 36,700 $ 5.74 4.69 - Options forfeited - $ - - - Options expired - $ - - - Options exercised (30,353 ) $ 0.06 - - Options Outstanding as of June 30, 2021 432,164 $ 4.86 5.15 $ 267,985 Options Exercisable as of June 30, 2021 287,840 $ 4.93 4.77 $ 166,419

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases
SCHEDULE OF OPERATING LEASES	SCHEDULE OF OPERATING LEASES Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of right-of-use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES	SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES 2021 Amounts due within twelve months of June 30 2021 $ 117,109 2022 49,824 2023 51,327 2024 52,866 2025 54,452 Thereafter 133,300 Total minimum lease payments 458,878 Less: effect of discounting (120,248 ) Present value of future minimum lease payments 338,631 Less: current obligations under leases 90,628 Long-term lease obligations $ 248,003

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS	SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS Six Months Ended June 30, 2021 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,387,360 $ 832,243 $ 1,715,466 $ 16,420 $ 4,951,489 Gross Profit $ 2,387,048 $ 94,033 $ (272,461 ) $ 16,082 $ 2,224,702 Segment Assets $ 1,587,888 $ (417,731 ) $ 1,301,196 $ 4,424,677 $ 6,896,030 Segment Profit (Loss) $ 980,562 $ (47,901 ) $ (1,656,786 ) $ (2,505,670 ) $ (3,229,795 ) Six Months Ended June 30, 2020 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Other Total Revenue $ 2,914,537 $ 870,637 $ 5,003,523 $ 7,260 $ 8,795,957 Gross Profit $ 2,914,537 $ 74,835 $ 648,276 $ 7,260 $ 3,644,908 Segment Assets $ 1,793,747 $ 243,603 $ 5,041,989 $ 4,652,944 $ 11,732,283 Segment Profit (Loss) $ 1,872,862 $ (72,955 ) $ 369,370 $ (2,531,561 ) $ (362,284 )

SCHEDULE OF BASIC AND DILUTIVE

SCHEDULE OF BASIC AND DILUTIVE INCOME (LOSS) PER SHARE (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Net (Loss) Income	$ (2,578,276)	$ (651,519)	$ (542,587)	$ 180,303	$ (3,229,795)	$ (362,284)
Numerator for basic and diluted EPS - income available to common Shareholders	$ (2,578,276)		$ (542,587)		$ (3,229,795)	$ (362,284)
Denominator for basic and diluted EPS – Weighted average shares	8,122,206		7,580,977		8,107,864	7,324,512
Basic and Diluted (Loss) Income per common share	$ (0.32)		$ (0.07)		$ (0.40)	$ (0.05)

ORGANIZATION AND BASIS OF PRE_3

ORGANIZATION AND BASIS OF PRESENTATION (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Entity Listings [Line Items]
Ownership percentage	100.00%
Bad debt expense	$ 0	$ 9,000
Recovery of bad debt	10,000	$ 0
Account receivable	1,504,037		$ 805,043
Warrants outstanding	$ 75,875
Number of options outstanding	432,164
Single Customer [Member]
Entity Listings [Line Items]
Account receivable	$ 630,000
Bonum Health Hub [Member]
Entity Listings [Line Items]
Investment Company, Gain (Loss) on Investment Not Meeting Guidelines	$ 143,891

SHORT TERM DEBT _ RELATED PAR_2

SHORT TERM DEBT – RELATED PARTIES (Details Narrative) - USD ($)	1 Months Ended
	Oct. 31, 2019	Oct. 31, 2018	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes payable related parties, current			$ 225,000	$ 225,000
Related Party Promissory Note [Member] | Community Specialty Pharmacy, LLC [Member] | Nikul Panchal [Member]
Short-term Debt [Line Items]
Debt, Current		$ 300,000
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Maturity Date		Oct. 15, 2021
Debt Conversion, Converted Instrument, Amount	$ 75,000
Debt Conversion, Converted Instrument, Shares Issued	25,000
Debt Instrument, Convertible, Conversion Price	$ 3
Notes Payable, Current	$ 225,000
Gain (Loss) on Extinguishment of Debt	$ 76,500

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	May 27, 2021	Apr. 15, 2021	Apr. 14, 2020	Jun. 30, 2021	Dec. 31, 2020
Howard A.Doss [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock			12,500
Mr.Donald G.Fell, Dr. Pamela Tenaerts and Mr. Michael L. Peterson [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock			8,987
Board of Directors [Member] | Stock Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program description	There is no time frame for the repurchase program, and such program will remain in place until a maximum of $1.0 million of the Company’s common stock has been repurchased or until such program is suspended or discontinued by the Board of Directors.
Common stock repurchase shares				0
Board of Directors [Member] | Stock Repurchase Program [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock repurchased value	$ 1,000,000
Board of Directors [Member] | 2021 Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase common stock		17,500
Grant date year		5 years
Options exercise price		$ 4.76
Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson [Member] | 2021 Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock		10,721
Fair value of restricted common stock		$ 55,000		$ 165,000
Stock based compensation				41,250
Shares price per share		$ 5.13
Mr. Peterson and Ms. Tenaerts [Member] | 2021 Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Redeemed or Called During Period, Shares	16,082
Michael L. Peterson and Dr. Pamela Tenaert [Member] | 2021 Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested number of shares	2,680
Charles L. Pope, and Christine L. Jennings [Member] | 2021 Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock	10,912
Fair value of restricted common stock	$ 41,250
Shares price per share	$ 3.78
Suren Ajjarapu [Member] | Employment Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock			49,020
Fair value of restricted common stock			$ 300,000
Stock based compensation					$ 391,841
Vested number of shares					49,020
Incremental value			$ 72,062
Legal Counsel [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted common stock			5,000
Two Thousand Twenty Equity Compensation Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted common stock			$ 107,100
Stock based compensation				26,775
Independent Director Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted common stock			$ 165,000
Stock based compensation				$ 41,250

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Warrants
Number of Outstanding Shares, Warrants, Outstanding Beginning | shares	82,751
Weighted Average Exercise Price, Outstanding Beginning | $ / shares	$ 1.33
Contractual Life in Years, Warrants, Outstanding Beginning	2 years 8 months 23 days
Intrinsic Value, Warrants, Outstanding Beginning | $	$ 352,951
Number of Outstanding Shares, Warrants granted | shares
Weighted Average Exercise Price, Warrants granted | $ / shares
Number of Outstanding Shares, Warrants expired or forfeited | shares	(6,876)
Weighted Average Exercise Price, Warrants expired or forfeited | $ / shares	$ 9
Number of Outstanding Shares, Warrants exercised | shares
Weighted Average Exercise Price, Warrants exercised | $ / shares
Number of Outstanding Shares, Warrants, Outstanding Ending | shares	75,875
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 0.64
Contractual Life in Years, Warrants, Outstanding Ending	2 years 5 months 12 days
Intrinsic Value, Warrants, Outstanding Ending | $	$ 286,939
Number of Outstanding Shares, Warrants, Exercisable Ending | shares	53,347
Weighted Average Exercise Price, Warrants, Exercisable Ending | $ / shares	$ 0.88
Contractual Life in Years, Warrants Exercisable Ending	1 year 3 months
Intrinsic Value, Warrants Exercisable Ending | $	$ 188,717

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants granted
Warrant [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Warrants granted	0
Warrants to purchase	6,876
Share-based Payment Arrangement, Noncash Expense	$ 0	$ 100,383

SCHEDULE OF ESTIMATE FAIR VALUE

SCHEDULE OF ESTIMATE FAIR VALUE OF STOCK OPTIONS (Details)	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Weighted-average expected volatility, maximum	0.25%
Expected life of options	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	102.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	207.00%

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - Stock Options [Member]	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning Balance | shares	425,817
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 4.44
Contractual Life in Years Outstanding, Beginning Balance	5 years 3 months 29 days
Intrinsic Value Outstanding, Beginning Balance | $	$ 597,322
Number of Options Exercisable, Beginning Balance | shares	282,167
Weighted Average Exercise Price Exercisable, Beginning Balance | $ / shares	$ 4.52
Contractual Life in Years Exercisable, Beginning Balance	4 years 6 months 21 days
Intrinsic Value Exercisable, Beginning Balance | $	$ 384,226
Number of Options, Granted | shares	36,700
Weighted Average Exercise Price, Granted | $ / shares	$ 5.74
Contractual Life in Years, Granted	4 years 8 months 8 days
Number of Options, Forfeited | shares
Weighted Average Exercise Price, Forfeited | $ / shares
Number of Options, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Number of Options, Exercised | shares	(30,353)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.06
Number of Options Outstanding, Ending Balance | shares	432,164
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	$ 4.86
Contractual Life in Years Outstanding, Ending Balance	5 years 1 month 24 days
Intrinsic Value Outstanding, Ending Balance | $	$ 267,985
Number of Options Exercisable, Ending Balance | shares	287,840
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 4.93
Contractual Life in Years Exercisable, Ending Balance	4 years 9 months 7 days
Intrinsic Value Exercisable, Ending Balance | $	$ 166,419

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Proceeds from Issuance of Common Stock		$ 5,994,424
Share-based Payment Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, granted	36,700
Number of shares available	30,353
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod]	four-year
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.74
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years
Proceeds from Issuance of Common Stock	$ 1,821
Share-based Payment Arrangement, Noncash Expense	$ 137,130	$ 245,903
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, granted	2,333,333
Second Amended and Restated 2019 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available	2,000,000
Option share description	beginning in 2021 and ending in 2029 (each a “Date of Determination”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator.

OTHER RECEIVABLES (Details Narr

OTHER RECEIVABLES (Details Narrative)	Aug. 14, 2020Integer	Aug. 31, 2020USD ($)Integer	Jul. 31, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)
Entity Listings [Line Items]
[custom:LossOnInventoryInvestment]				$ 1,225,141		$ 1,225,141
Integra [Member] | Studebaker Defense Group, LLC [Member]
Entity Listings [Line Items]
Down payment			$ 500,000
[custom:NumberOfNitrileGlovesDelivered] | Integer	180,000
Loss Contingency, Damages Sought, Value			$ 500,000
[custom:LossOnInventoryInvestment]						500,000
Integra [Member] | Sandwave Group Dsn Bhd [Member]
Entity Listings [Line Items]
Down payment		$ 581,250
[custom:NumberOfNitrileGlovesDelivered] | Integer		150,000
Loss Contingency, Damages Sought, Value		$ 581,250
[custom:LossOnInventoryInvestment]						581,250
Integra [Member] | Crecom Burj Group SDN BHD [Member]
Entity Listings [Line Items]
Loss Contingency, Damages Sought, Value		$ 581,250
Bonum Health, LLC [Member]
Entity Listings [Line Items]
[custom:LossOnInventoryInvestment]						$ 143,891

CONTINGENCIES (Details Narrativ

CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Jan. 31, 2020	Jun. 30, 2021
Loss Contingencies [Line Items]
Loss Contingency, Damages Paid, Value		$ 450,000
Compensatory Damages [Member]
Loss Contingencies [Line Items]
Complaint seeks	$ 425,000
Punitive Damages [Member]
Loss Contingencies [Line Items]
Complaint seeks	$ 1,275,000
Damages Sought is Unclear [Member]
Loss Contingencies [Line Items]
Complaint seeks		$ 425,000

SCHEDULE OF OPERATING LEASES (D

SCHEDULE OF OPERATING LEASES (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Lessor, Lease, Description [Line Items]
Initial Recognition of right-of-use assets at January 1, 2019	$ 323,221	$ 387,371
Lease 1 [Member]
Lessor, Lease, Description [Line Items]
Initial Lease Term	December 2017 to December 2021
Renewal Term	January 2021 to December 2024
Initial Recognition of right-of-use assets at January 1, 2019	$ 534,140
Incremental Borrowing Rate	10.00%
Lease 2 [Member]
Lessor, Lease, Description [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Initial Recognition of right-of-use assets at January 1, 2019	$ 313,301
Incremental Borrowing Rate	10.00%

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Leases
2021	$ 117,109
2022	49,824
2023	51,327
2024	52,866
2025	54,452
Thereafter	133,300
Total minimum lease payments	458,878
Less: effect of discounting	(120,248)
Present value of future minimum lease payments	338,631
Less: current obligations under leases	90,628	$ 131,153
Long-term lease obligations	$ 248,003

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases
[custom:ReductionInLeaseLiability-0]	$ 384,110
Operating Lease, Right-of-Use Asset, Amortization Expense	64,150	$ 47,799
[custom:AmortizationOfLeaseLiability]	$ 63,829	$ 42,477

SCHEDULE OF BUSINESS INTERESTS

SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 1,898,254	$ 6,592,637	$ 4,951,489	$ 8,795,957
Gross Profit	841,391	2,004,772	2,224,702	3,644,908
Segment Assets	6,896,030	11,732,283	6,896,030	11,732,283	$ 9,792,702
Segment Profit (Loss)			(3,229,795)	(362,284)
Trxade, Inc. [Member]
Segment Reporting Information [Line Items]
Revenue			2,387,360	2,914,537
Gross Profit			2,387,048	2,914,537
Segment Assets	1,587,888	1,793,747	1,587,888	1,793,747
Segment Profit (Loss)			980,562	1,872,862
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			832,243	870,637
Gross Profit			94,033	74,835
Segment Assets	(417,731)	243,603	(417,731)	243,603
Segment Profit (Loss)			(47,901)	(72,955)
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			1,715,466	5,003,523
Gross Profit			(272,461)	648,276
Segment Assets	1,301,196	5,041,989	1,301,196	5,041,989
Segment Profit (Loss)			(1,656,786)	369,370
Other Segments [Member]
Segment Reporting Information [Line Items]
Revenue			16,420	7,260
Gross Profit			16,082	7,260
Segment Assets	$ 4,424,677	$ 4,652,944	4,424,677	4,652,944
Segment Profit (Loss)			$ (2,505,670)	$ (2,531,561)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) $ in Millions	Jul. 18, 2021USD ($)
Subsequent Event [Member] | Board of Directors [Member] | Maximum [Member]
Subsequent Event [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 9